Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone marrow transplantation (Basingstoke) 2021-04, Vol.56 (4), p.974-977
Hauptverfasser: Ghafouri, Sanaz, Timmerman, John, Larson, Sarah, Mead, Monica D.
Format: Artikel
Sprache:eng
Schlagworte:
631/67/1059/2325
692/699/1541/1990/291
Biophysics
Care and treatment
Cell Biology
Cell therapy
Cellular therapy
Central nervous system diseases
Correspondence
Development and progression
Hematology
Immunology
Internal Medicine
Life Sciences & Biomedicine
Lymphocytes T
Lymphoma
Medicine
Medicine & Public Health
Methods
Non-Hodgkin's lymphoma
Non-Hodgkin's lymphomas
Oncology
Patient outcomes
Public Health
Science & Technology
Stem Cells
Toxicity
Transplantation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-020-01099-4